The diagnosis of cancer therapeutics-related cardiac dysfunction
10.16571/j.cnki.1008-8199.2019.04.020
- VernacularTitle: 肿瘤治疗相关心脏损伤诊断的研究进展
- Author:
Peng XU
1
;
Jian-ping LAI
1
;
An-wen LIU
1
Author Information
1. Department of Oncology,The Second Affiliated Hospital to Nanchang University, Nanchang 330006,Jiangxi, China
- Publication Type:Journal Article
- Keywords:
cardiac dysfunction;
cancer therapy;
diagnose methods
- From:
Journal of Medical Postgraduates
2019;32(4):437-442
- CountryChina
- Language:Chinese
-
Abstract:
Cardiac dysfunction is a common and severe side-effect after cancer therapy including thoracic radiation or cytotoxic agents. With the development of the cancer therapy method and the agents, the survival time of the patients has improved while most cancer patients could live with tumor or even be cured. The rate of cancer therapeutics-related cardiac dysfunction have obviously increased which seriously affect the time and life quality of patients with tumor. But there are no authoritative consensus criteria or guideline to diagnose CTRCD at present while it is difficult to identify CTRCD with primary heart disease. In this article，we summarized some diagnosis methods which could identify early CTRCD，and then we may give early drug intervention as soon as possible to reduce the incidence and remission rate of cardiovascular events.
